Experimental study on interferon α2b combined with marine and thymosin al in the treatment of chronic hepatitis B.

To evaluate the experimental efficacy of interferon α2b comibined with marine and thymosin α1. 98 chronic hepatits B patients were enrolled and randomized into the therapy group and the control group. 49 cases in the therapy group received interferon α2b and thymosin al for 13weeks, at last interferon α2b simultaneously for 26 weeks; 49 cases in the control group received interferon α2b alone for 52 weeks. During the treatment blood routine examination ALT 、 HBeAg、 Anti - HBe 、HBVDNA and HA were termly checked and measured. All 98 patients completed the study. The rates for ALT and HA to recover to mormal and the rates for HBeAg and HBVDNA to change to be negative in combination group were superior to those in interferon α2b group. (81.6% vs 53.1%, P 0.005; 44.9% vs 22.4% , P 0.0025; 42.9% vs 20.4% , P 0.025; 79.6% vs51.0%,P 0.005) .The efficacy of combination therapy appeared to be better than interferon α2b group.